Literature DB >> 6626985

Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease.

B Scatton, F Javoy-Agid, L Rouquier, B Dubois, Y Agid.   

Abstract

Dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, noradrenaline, serotonin and 5-hydroxyindoleacetic acid concentrations were measured in several cortical areas, hippocampus and, for comparison, in the caudate nucleus, from control subjects and parkinsonian patients. Substantial amounts of these compounds were detected in hippocampus, and entorhinal, cingulate and frontal cerebral cortices of control subjects. In patients who had discontinued L-DOPA at least 4 days before death (group I), the levels of dopamine and its metabolites were reduced in these cortical areas, although to a lesser extent than in the caudate nucleus. In patients on continuous L-DOPA treatment (i.e. having received the last dose of L-DOPA 0-24 h before death, group II), cortical dopamine levels were less reduced than in group I patients and dopamine metabolite levels were similar to those of controls. The ratio of the concentrations of homovanillic acid to dopamine was increased in the caudate nucleus and entorhinal cortex but not in the other cortical areas of group I parkinsonian patients. Cortical noradrenaline concentrations were also diminished, the decrement being similar in groups I and II. A reduction of serotonin and its metabolite in the caudate nucleus and hippocampus and a diminution of serotonin levels in the frontal cortex were observed in group I patients. In these patients, the 5-hydroxyindoleacetic acid to serotonin ratio was increased in the caudate nucleus and frontal cortex but not in the other cortical areas. The results are discussed in relation to the pathophysiology of the psychiatric and cognitive disturbances observed in some parkinsonian patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6626985     DOI: 10.1016/0006-8993(83)90993-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  134 in total

Review 1.  Neural transplantation for Parkinson's disease.

Authors:  I Date; T Ohmoto
Journal:  Cell Mol Neurobiol       Date:  1999-02       Impact factor: 5.046

2.  Reversal of stress-induced dendritic atrophy in the prefrontal cortex by intracranial self-stimulation.

Authors:  K Ramkumar; B N Srikumar; D Venkatasubramanian; R Siva; B S Shankaranarayana Rao; T R Raju
Journal:  J Neural Transm (Vienna)       Date:  2011-12-14       Impact factor: 3.575

3.  Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease.

Authors:  S Engelborghs; B Marescau; P P De Deyn
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

Review 4.  The serotonin 5-HT1D receptor: a progress review.

Authors:  C Waeber; P Schoeffter; D Hoyer; J M Palacios
Journal:  Neurochem Res       Date:  1990-06       Impact factor: 3.996

5.  Age- and duration-dependent effects of MPTP on cortical serotonin systems.

Authors:  Twum A Ansah; Marcus C Ferguson; Tultul Nayyar; Ariel Y Deutch
Journal:  Neurosci Lett       Date:  2011-09-21       Impact factor: 3.046

Review 6.  Pathologic correlates of dementia in individuals with Lewy body disease.

Authors:  Joshua A Sonnen; Nadia Postupna; Eric B Larson; Paul K Crane; Shannon E Rose; Kathleen S Montine; James B Leverenz; Thomas J Montine
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

Review 7.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

Review 8.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

9.  Changes to Ventilation, Vocalization, and Thermal Nociception in the Pink1-/- Rat Model of Parkinson's Disease.

Authors:  Rebecca A Johnson; Cynthia A Kelm-Nelson; Michelle R Ciucci
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

10.  Serotonergic modulation of Neural activities in the entorhinal cortex.

Authors:  Saobo Lei
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.